Patents by Inventor Nicholas T. Rapson

Nicholas T. Rapson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080279852
    Abstract: The present invention relates to methods of treating a human patient suffering from rheumatoid arthritis, comprising: obtaining a CHO cell comprising antibody heavy and light chain genes which are constituted of cDNA and in a form that enables balanced expression of the light and heavy chains of a human or humanized recombinant antibody; culturing the CHO cell in a serum-free media; purifying the resulting recombinant antibody; and administering a therapeutically effective amount of the antibody expressed and glycosylated in a CHO cell expression system to said human patient.
    Type: Application
    Filed: July 28, 2008
    Publication date: November 13, 2008
    Inventors: Martin J. Page, James S. Crowe, Nicholas T. Rapson, Michael J. Keen
  • Publication number: 20030035799
    Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
    Type: Application
    Filed: May 16, 2002
    Publication date: February 20, 2003
    Applicant: Glaxo Wellcome Inc.
    Inventors: Martin J. Page, James S. Crowe, Nicholas T. Rapson, Michael J. Keen
  • Patent number: 5633162
    Abstract: A biochemically defined culture medium for culturing engineered Chinese hamster ovary (CHO) cell lines, which is essentially free from protein, lipid and carbohydrate isolated from an animal source, having water, an osmolality regulator, a buffer, an energy source, amino acids including L-glutamine, an inorganic or recombinant iron source, and a synthetic or recombinant growth factor, and optionally non-ferrous metal ions vitamins and cofactors. Also cells adapted to grow in such a culture medium.
    Type: Grant
    Filed: March 4, 1994
    Date of Patent: May 27, 1997
    Assignee: Glaxo Wellcome Inc.
    Inventors: Michael J. Keen, Nicholas T. Rapson
  • Patent number: 5316938
    Abstract: A biochemically defined culture medium for culturing engineered Chinese hamster ovary (CHO) cell lines, which is essentially free from protein, lipid and carbohydrate isolated from an animal source, comprising water, an osmolality regulator, a buffer, an energy source, amino acids including L-glutamine, an inorganic or recombinant iron source, and a synthetic or recombinant growth factor, and optionally non-ferrous metal ions vitamins and cofactors; also cells adapted to grow in such a culture medium.
    Type: Grant
    Filed: December 18, 1992
    Date of Patent: May 31, 1994
    Assignee: Burroughs Wellcome Co.
    Inventors: Michael J. Keen, Nicholas T. Rapson
  • Patent number: RE39792
    Abstract: A biochemically defined culture medium for culturing engineered Chinese hamster ovary (CHO) cell lines, which is essentially free from protein, lipid and carbohydrate isolated from an animal source, having water, an osmolality regulator, a buffer, an energy source, amino acids including L-glutamine, an inorganic or recombinant iron source, and a synthetic or recombinant growth factor, and optionally non-ferrous metal ions vitamins and cofactors. Also cells adapted to grow in such a culture medium. REEXAMINATION RESULTS The questions raised in reexamination request no. 90/006656, filed Jun. 2, 2003 have been considered and the results thereof are reflected in this reissue patent which constitutes the reexamination certificate required by 35 U.S.C. 307 as provided in 37 CFR 1.570(e), for ex parte reexaminations, or the reexamination certificate required by 35 U.S.C. 316 as provided in 37 CFR 1.997(e) for inter partes reexaminations.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: August 21, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael J. Keen, Nicholas T. Rapson